Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)

J. C. Goh; J. Coward; B. Gao; I. Pires Da Silva; M. Voskoboynik; D. Day; A. Body; H. K. Gan; X. Li; J. Sun; C. Fei; L. Yang; M. Millward

doi:10.1016/j.annonc.2021.10.172

Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)

J. C. Goh, J. Coward, B. Gao, I. Pires Da Silva, M. Voskoboynik, D. Day, A. Body, H. K. Gan, X. Li, J. Sun, C. Fei, L. Yang, M. Millward

Internal Medicine

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

3 Citations (Web of Science)

Original language	English
Pages (from-to)	S1446-S1447
Number of pages	2
Journal	Annals of Oncology
Volume	32
DOIs	https://doi.org/10.1016/j.annonc.2021.10.172
Publication status	Published - Dec 2021
Event	ESMO Immuno-Oncology Congress 2021 - Duration: 8 Dec 2021 → 11 Dec 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2021.10.172Licence: Other

Cite this

Goh, J. C., Coward, J., Gao, B., Da Silva, I. P., Voskoboynik, M., Day, D., Body, A., Gan, H. K., Li, X., Sun, J., Fei, C., Yang, L., & Millward, M. (2021). Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC). Annals of Oncology, 32, S1446-S1447. https://doi.org/10.1016/j.annonc.2021.10.172

@article{9bc5dc83aac94b4392a08802c8ede03b,

title = "Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)",

author = "Goh, {J. C.} and J. Coward and B. Gao and {Da Silva}, {I. Pires} and M. Voskoboynik and D. Day and A. Body and Gan, {H. K.} and X. Li and J. Sun and C. Fei and L. Yang and M. Millward",

year = "2021",

month = dec,

doi = "10.1016/j.annonc.2021.10.172",

language = "English",

volume = "32",

pages = "S1446--S1447",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

note = "ESMO Immuno-Oncology Congress 2021 ; Conference date: 08-12-2021 Through 11-12-2021",

}

Goh, JC, Coward, J, Gao, B, Da Silva, IP, Voskoboynik, M, Day, D, Body, A, Gan, HK, Li, X, Sun, J, Fei, C, Yang, L & Millward, M 2021, 'Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)', Annals of Oncology, vol. 32, pp. S1446-S1447. https://doi.org/10.1016/j.annonc.2021.10.172

TY - JOUR

T1 - Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)

AU - Goh, J. C.

AU - Coward, J.

AU - Gao, B.

AU - Da Silva, I. Pires

AU - Voskoboynik, M.

AU - Day, D.

AU - Body, A.

AU - Gan, H. K.

AU - Li, X.

AU - Sun, J.

AU - Fei, C.

AU - Yang, L.

AU - Millward, M.

PY - 2021/12

Y1 - 2021/12

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=uwapure5-25&SrcAuth=WosAPI&KeyUT=WOS:000731051400156&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1016/j.annonc.2021.10.172

DO - 10.1016/j.annonc.2021.10.172

M3 - Abstract/Meeting Abstract

SN - 0923-7534

VL - 32

SP - S1446-S1447

JO - Annals of Oncology

JF - Annals of Oncology

T2 - ESMO Immuno-Oncology Congress 2021

Y2 - 8 December 2021 through 11 December 2021

ER -

Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)

UN SDGs

Access to Document

Other files and links

Cite this